CHOONG ANG VACCINE LABORATORY: debt-to-equity, ROE and more
KOSDAQ, Legal name CHOONG ANG VACCINE LABORATORY
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 16.6%
- Equity ratio
- 85.8%
- ROE
- 5.8%
- Op. margin
- 13.2%
- Rev. growth
- 7.6%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩200 | 30.1% |
| 2024 | ₩170 | 23.7% |
| 2023 | ₩150 | 24.2% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 21.5% | 82.3% | 8.2% | 11.1% | n/a |
| FY2022 consolidated | 20.5% | 83.0% | 4.2% | 10.9% | -3.9% |
| FY2023 separate | 19.8% | 83.5% | 6.0% | 16.7% | 6.5% |
| FY2024 separate | 18.7% | 84.3% | 6.6% | 12.6% | 8.9% |
| FY2025 separate | 16.6% | 85.8% | 5.8% | 13.2% | 7.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩40.9B | ₩39.3B | ₩41.9B | ₩45.6B | ₩49.1B |
| Operating profit | ₩4.5B | ₩4.3B | ₩7.0B | ₩5.8B | ₩6.5B |
| Pre-tax income | ₩6.4B | ₩4.8B | ₩7.5B | ₩8.0B | ₩6.6B |
| Net income | ₩7.6B | ₩4.0B | ₩6.0B | ₩6.9B | ₩6.2B |
| Total assets | ₩113.0B | ₩114.9B | ₩119.6B | ₩123.3B | ₩122.8B |
| Total liabilities | ₩20.0B | ₩19.6B | ₩19.8B | ₩19.4B | ₩17.4B |
| Total equity | ₩93.0B | ₩95.3B | ₩99.8B | ₩103.9B | ₩105.4B |
| Paid-in capital | ₩5.0B | ₩5.0B | ₩5.0B | ₩5.0B | ₩5.0B |
| Debt/equity (source value) | 21.5% | 20.5% | 19.8% | 18.7% | 16.6% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1994-10-04
- Listed
- 03/10/31
- Employees
- 194
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1601110042533
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 중앙백신Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.